

## Indium-mediated barbier allylations of hydroxyanthraquinones: an expedient synthesis of novel 10-alkenyl-10-hydroxy-9(10H)-anthracenones

Subodh Kumar\*, Vijay Kumar and Swapandeep Singh Chimni

Department of Chemistry, Guru Nanak Dev University, Amritsar - 143 005, India

Indium-mediated allylations of 1,8-dihydroxy-9,10-anthraquinone with allyl, cinnamyl and crotonyl bromides/chlorides and 1,4- and 1,5- dihydroxy derivatives with allyl bromide in THF–MeOH–H<sub>2</sub>O gave the respective 10-alkenyl-10-hydroxy-9(10H)-anthracenones in excellent yields.

Anthracenones substituted at C-10 have attained paramount significance<sup>1</sup> due to their broad spectrum biological activities including antipsoriatic activity and leukotriene biosynthesis inhibition. Naturally occurring<sup>2</sup> 1,8-dihydroxy-9(10H)-anthracenones, (R)- and (S)- aloin A and B derivatives (Fig. 1) possess a hydroxy group at C-10. Chemical transformation of hydroxyanthraquinones leads to the formation of either 9,10-dihydroxyanthracenes or 9- / 10-deoxyanthracenones<sup>3</sup> and the formation of 10-hydroxyanthracenones is not known. In the case of hydroxyanthraquinones, the poor reactivity of C=O and the ease in generation of oxa anions under basic conditions have restricted the addition of carbon nucleophiles. In the last few years, indium-mediated Barbier-type reactions have shown immense potential for allylations even on hydroxy carbonyl substrates.<sup>4</sup> We have found that indium-mediated allylations of dihydroxy-9,10- anthraquinones with their phenolic OH groups provide a unique methodology for the synthesis of 10-alkenyl-10-hydroxy-9(10H)-anthracenone derivatives.




Fig. 1

The reaction of 1,8-dihydroxy-9,10-anthraquinone (**1**) with allyl bromide (**5**) and indium metal in THF – MeOH –H<sub>2</sub>O (5 : 5 : 1) at 30–32°C provided two isomeric compounds, M<sup>+</sup> m/z 282, **8** (90%), m.p. 121–23°C and **14** (5%), thick liquid, after hydrolysis with aqueous hydrochloric acid. In their <sup>1</sup>H NMR spectra, both the compounds exhibit two doublets and one triplet due to the anthracenone ring. In the case of the major, higher R<sub>F</sub> component, the triplet due to C-3 and C-6H being *para* to a carbonyl group appears as the most downfield signal (δ 7.51) and its phenolic OH appears at δ 12.04 due to H-bonding with carbonyl. In the <sup>1</sup>H NMR of the minor component the doublet due to ArH *ortho* to carbonyl appears as the most downfield signal (δ 7.78) and the phenolic OH signal is shifted upfield to δ 8.17 due to lack of H-bonding. These spectral data conform to structures **8** and **14**, respectively for major and minor components. The formation of **8** as the major component could be attributed to the lesser steric hindrance at

C<sub>10</sub>=O than at C<sub>9</sub>=O in **1**. This reaction failed to proceed in THF – H<sub>2</sub>O (Barbier) and in dry THF (both Barbier and Grignard) conditions.

The reaction of **1** with cinnamyl bromide failed to proceed at 30°C but on increasing the reaction temperature to 40–45°C gave anthracenone **9** (82%). In its <sup>1</sup>H NMR spectrum, the appearance of a 2H doublet at δ 2.65 confirms it as the alpha addition product and the corresponding *gamma* addition product could not be detected. 3-Chlorobutene with **1** gave a compound (30%), m.p. 83°C, M<sup>+</sup> m/z 296 which in its <sup>1</sup>H NMR spectrum exhibits two Me doublets at δ 0.78 and 1.50 in 9:1 ratio along with other signals and could be a mixture of **10** and **15** which could not be separated. Therefore, in indium-induced reactions of substituted allyl bromides, *alpha* addition is the preferred route over *gamma* addition. 9,10-Anthracenone (**4**) and its 1,4- (**2**) and 1,5- (**3**) dihydroxy derivatives gave the respective anthracenones **13**, **11** and **12** in good yields with allyl bromide.

Cinnamyl bromide and **2** did not give the desired addition product but formed leucoquinazirine (60%) – the reduced product of **2**, cinnamyl alcohol and cinnamyl methyl ether. The preformed cinnamyl indium complex also reacts with **2** in dry THF to give leucoquinazirine (70%) and cinnamyl alcohol. Probably, the cinnamyl indium complex transfers an electron to reduce **2** and itself is converted to a radical cation which is quenched with the solvent to give cinnamyl alcohol / cinnamyl methyl ether.

Therefore, indium-mediated Barbier allylations of α,ω-dihydroxy-9,10-anthraquinones provide the respective 10-alkenyl-10-hydroxy-9(10H)anthracenones in excellent yields and, presumably due to the poor basicity of the indium reagents, even the acidic phenolic OH groups do not interfere.

A preliminary screening profile shows that cancer cell lines NCI-H460, MCF-7 and SF-268 show less than 35 % growth with **8**, **11** and **12** and show –53 to –73% growth with **9** at 10<sup>–4</sup>M concentration.

### Experimental


For general experimental see ref 5.

**Barbier allylations of 9,10-anthraquinones (1–4):** general procedure: In a typical experiment 1,8-dihydroxyanthraquinone (750 mg, 3.1 mmol), allyl bromide (654 mg, 5.4 mmol) and indium metal (413 mg, 3.6 mmol) were taken in a THF (10ml) – CH<sub>3</sub>OH (10ml) – water (5 ml) mixture and the reaction mixture was stirred at 30±2°C for about 4–6 h. The reaction mixture was then quenched with saturated brine solution and dilute HCl until it became clear. It was extracted (CHCl<sub>3</sub>), the extract was dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent was removed. The residue was column chromatographed (silica gel, 60–120 mesh) to isolate pure **8** and **14**. A similar procedure was followed for all the reactions except when stated.

**10-[1-(prop-2-enyl)]-1,8,10-trihydroxy-9(10H)-anthracenone (8):** (90%), yellow solid, m.p. 121–23°C (ethyl acetate : methanol); M<sup>+</sup> m/z 282 (M<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.56(1H, s, OH), 2.59–2.62 (2H,

\* To receive any correspondence. E-mail: sk\_gndu@yahoo.com

† This is a Short Paper, there is therefore no corresponding material in *J. Chem. Research (M)*.



m, CH<sub>2</sub>), 4.58–4.90 (2H, m, =CH<sub>2</sub>), 5.10–5.24 (1H, m, =CH), 6.83 (2H, d, *J* = 8.2, H-2,7), 7.32 (2H, d, *J* = 8.2, H-4,5), 7.51 (2H, t, *J* = 8.2, H-3,6), 12.04 (2H, s, 2 × OH); <sup>13</sup>C NMR (normal/DEPT - 135) (CDCl<sub>3</sub>): δ 54.23 (-ve, CH<sub>2</sub>), 72.96 (ab, C), 114.32 (ab, C), 116.8 (+ve, CH), 119.87 (-ve, CH<sub>2</sub>), 130.84 (+ve, CH), 136.58 (+ve, CH), 148.58 (ab, C), 161.77 (ab, C), 192.13 (ab, C). λ<sub>max</sub> (EtOH): 374 (8 × 10<sup>2</sup>), 299 (7.4 × 10<sup>2</sup>), 267 (6.2 × 10<sup>2</sup>) nm. (Found C 72.6; H 4.7%. C<sub>17</sub>H<sub>14</sub>O<sub>4</sub> requires C 72.34; H 4.96%).

**10-[1-(3-phenylprop-2-enyl)]-1,8,10-trihydroxy-9(10H)-anthracenone (9)**: The reaction was performed at 40 ± 2°C. (82%); yellow solid; m.p. 179°C (ethyl acetate - methanol); M<sup>+</sup> *m/z* 358(M<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.51 (1H, s, OH), 2.65 (2H, d, *J* = 7.5, CH<sub>2</sub>), 5.51–5.67 (1H, m, =CH), 5.92 (1H, m, CH), 6.87 (2H, d, *J* = 8.4, H-2,8), 7.04–7.24 (5H, m, Ph), 7.34 (2H, d, *J* = 8.4, H-4,5), 7.52 (2H, t, *J* = 8.4, H-3,6), 12.00 (2H, s, 2 × OH); <sup>13</sup>C NMR (normal / DEPT - 135) (CDCl<sub>3</sub>): δ 53.41 (-ve, CH<sub>2</sub>), 73.62 (ab, C), 114.17 (ab, C), 116.57 (+ve, CH), 117.07 (+ve, CH), 122.39 (+ve, CH), 126.01 (+ve, CH), 127.42 (+ve, CH), 128.39 (+ve, CH), 135.02 (+ve, CH), 136.47 (+ve, CH), 136.67 (ab, C), 148.69 (ab, C), 162.18 (ab, C), 192.02 (ab, C). λ<sub>max</sub> (EtOH): 374 (8.7 × 10<sup>2</sup>), 294 (9.4 × 10<sup>2</sup>), 253 (2.2 × 10<sup>3</sup>) nm. (Found C 76.8; H 4.8%. C<sub>23</sub>H<sub>18</sub>O<sub>4</sub> requires C 77.09; H 5.03%).

**10-[3-(but-1-enyl)]-1,8,10-trihydroxy-9(10H)-anthracenone (10/15)**: The reaction was performed at 50 ± 2°C and took 12h for completion. (30%), m.p. 83°C (CH<sub>2</sub>Cl<sub>2</sub> - MeOH); M<sup>+</sup> *m/z* 296(M<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.78(1/10 3H, d, *J* = 6.8Hz, CH<sub>3</sub>), 1.50(9/10 3H, d, *J* = 6.2Hz, CH<sub>3</sub>), 2.42–2.65(2H, m, CH<sub>2</sub>), 4.73–5.09(2H, m, CH<sub>2</sub>), 5.30–5.48(1H, m, =CH), 6.88–6.95(2H, m, anth -H), 7.21–7.41(2H, m, anth -H), 7.51–7.58(2H, m, anth -H), 12.01, 12.04(2H, s, OH). (Found C 73.1; H 5.3%. C<sub>18</sub>H<sub>16</sub>O<sub>4</sub> requires C 72.97; H 5.41%).

**10-[1-(prop-2-enyl)]-1,4,10-trihydroxy-9(10H)-anthracenone (11)**: (97%) brown solid, m.p. 108°C (CH<sub>2</sub>Cl<sub>2</sub> - MeOH); M<sup>+</sup> *m/z* 282(M<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.63–3.07(2H, m, CH<sub>2</sub>), 3.39 (s, 1H, OH), 4.52–4.80(2H, m, =CH<sub>2</sub>), 4.94–5.12(1H, m, =CH), 6.74 (1H, d, *J* = 9.0, H-3), 7.00 (1H, d, *J* = 9.0, H-2), 7.47 (1H, t, *J* = 7.6, H-6), 7.67 (1H, t, *J* = 7.6, H-7), 7.78 (1H, d, *J* = 7.6, H-5), 8.14 (1H, d, *J* = 7.6, H-8), 8.30 (s, 1H, OH), 12.39 (s, 1H, OH); <sup>13</sup>C NMR (normal/DEPT - 135) (CDCl<sub>3</sub>): δ 48.27 (-ve, CH<sub>2</sub>), 74.47 (ab, C), 114.16 (ab, C), 118.01 (+ve, CH), 120.03 (-ve, CH<sub>2</sub>), 125.23 (+ve, CH), 126.41 (+ve, CH), 126.53 (+ve, CH), 127.01 (ab, C), 128.24 (+ve, CH), 129.75 (ab, C), 130.57 (+ve, CH), 134.13 (+ve, CH), 145.39 (ab, C), 147.36 (ab, C), 156.08 (ab, C), 187.86 (ab, C). λ<sub>max</sub> (EtOH): 513 (7.3 × 10<sup>2</sup>), 466 (4.16 × 10<sup>3</sup>), 274 (11.1 × 10<sup>3</sup>), 256 (10.6 × 10<sup>3</sup>) nm. (Found C 72.7; H 5.2%. C<sub>17</sub>H<sub>14</sub>O<sub>4</sub> requires C 72.34; H 4.96%).

**10-[1-(prop-2-enyl)]-1,5,10-trihydroxy-9(10H)-anthracenone (12)**: (96%), yellow solid, m.p. 172°C (ethyl acetate - MeOH); M<sup>+</sup> *m/z* 282(M<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.70–3.07(2H, m, CH<sub>2</sub>), 3.36 (1H, s, OH), 4.60–4.89(2H, m, =CH<sub>2</sub>), 4.96–5.13(1H, m, =CH), 6.90 (1H, d, *J* = 8.2Hz, anth-H), 7.21 (1H, d, *J* = 8.2, anth -H), 7.28 (1H, d, *J* = 8.2, anth-H), 7.42 (1H, t, *J* = 8.2Hz, anth -H), 7.54 (1H, t, *J* = 8.2Hz, anth-H), 7.82 (1H, d, *J* = 8.2Hz, anth-H), 8.86 (1H, s, OH), 12.79 (s, 1H, OH); <sup>13</sup>C NMR (normal / DEPT - 135) (CDCl<sub>3</sub>): δ 49.47(-ve, CH<sub>2</sub>), 74.52 (ab, C), 116.02 (+ve, CH), 116.5 (+ve, CH), 118.28(+ve, CH), 119.76 (-ve, CH<sub>2</sub>), 122.24 (+ve, CH), 128.92 (+ve, CH), 130.99 (+ve, CH), 135.97 (+ve, CH), 155.40 (ab, C), 162.35

(ab, C), 187.86 (ab, C). λ<sub>max</sub> (EtOH): 343 (7 × 10<sup>2</sup>), 293 (11.1 × 10<sup>2</sup>), 269 (9 × 10<sup>2</sup>) nm. (Found C 72.0; H 5.0%. C<sub>17</sub>H<sub>14</sub>O<sub>4</sub> requires C 72.34; H 4.96%).

**10-[1-(prop-2-enyl)]-10-hydroxy-9(10H)-anthracenone (13)**: (83%); yellow solid, m.p. 106°C (CH<sub>2</sub>Cl<sub>2</sub> - MeOH) (Lit.<sup>6</sup> m.p. 108°C); M<sup>+</sup> *m/z* 250(M<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.63(1H, s, OH); 2.68(2H, d, *J* = 7.4Hz, CH<sub>2</sub>), 4.53–4.84(2H, m, =CH<sub>2</sub>), 5.02–5.20(1H, m, =CH), 7.41 (2H, t, *J* = 8.4Hz, H-3,6), 7.64 (2H, t, *J* = 8.4Hz, H-2,7), 7.88 (2H, d, *J* = 8.4Hz, H-4,5), 8.15 (2H, d, *J* = 8.4Hz, H-1,8); <sup>13</sup>C NMR (normal/DEPT - 135) (CDCl<sub>3</sub>): δ 52.86 (-ve, CH<sub>2</sub>), 72.21(ab, C), 119.46 (-ve, CH<sub>2</sub>), 125.66 (+ve, CH), 126.33 (+ve, CH), 127.41 (+ve, CH), 130.35 (+ve, CH), 130.91(ab, C), 133.04 (+ve, CH), 146.85 (ab, C), 183.24 (ab, C). λ<sub>max</sub> (EtOH): 274 (1.64 × 10<sup>3</sup>) nm.

**10-[1-(prop-2-enyl)]-1,8,9-trihydroxy-10(9H)-anthracenone (14)**: (5%), thick oil, M<sup>+</sup> *m/z* 282(M<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.14 (2H, d, *J* = 7.2, CH<sub>2</sub>), 4.50–4.74 (2H, m, =CH<sub>2</sub>), 4.85–5.05 (1H, m, =CH), 5.61 (1H, s, OH), 7.16 (2H, d, *J* = 8.0, H-2,7), 7.36 (2H, t, *J* = 8.0, H-3,6), 7.78 (2H, d, *J* = 8.0, H-4,5), 8.17 (2H, s, 2 × OH); <sup>13</sup>C NMR (normal/DEPT - 135) (CDCl<sub>3</sub>): δ 44.67 (-ve, CH<sub>2</sub>), 76.37 (ab, C), 119.25 (+ve, CH), 120.30 (-ve, CH<sub>2</sub>), 124.66 (+ve, CH), 128.84 (ab, C), 129.40 (+ve, CH), 130.84 (+ve, CH), 131.54 (ab, C), 154.51 (ab, C), 184.26 (ab, C).

We thank CSIR, New Delhi (01 (1530) 98/EMR-II) for financial Assistance and NIH, USA for bioactivity studies.

Received 15 February 2000; accepted 26 June 2000  
Paper 99/163

## References

- (a) R.A. Earl, R. Zaczek, C.A. Teleha, B.N. Fisher, C.M. Macaig, M.E. Marynowski, A.R. Logue, S.W. Tam, W.J. Tinker, S.M. Huang and R.J. Chorvat, *J. Med. Chem.*, 1998, **41**, 4615; (b) K. Muller and H. Prinz, *J. Med. Chem.*, 1997, **40**, 2780 and references there in; (c) P.J. Hayden, K. E. Free and C.F. Chignell, *Mol. Pharmacol.* 1994, **46**, 186.
- H.W. Rauwald and K. Lohase, *Planta Med.*, 1992, **58**, 259. (b) H.D. Hoeltje, K. Stahl, K. Lohase and H.W. Rauwald, *Arch. Pharm.*, 1991, **324**, 859.
- H. Prinz, W. Wiegrebe and K. Muller, *J. Org. Chem.*, 1996, **61**, 2853. (b) H. Prinz, T. Burgemeister, W. Wiegrebe and K. Muller, *J. Org. Chem.*, 1996, **61**, 2857.
- (a) C.J. Li and T.H. Chan, *Tetrahedron*, 1999, **55**, 11149; (b) C.J. Li, *Chem. Rev.*, 1993, **93**, 2023; (c) C.J. Li, *Tetrahedron*, 1996, **52**, 5643; (d) L.A. Paquette and T.M. Mitzel, *J. Am. Chem. Soc.*, 1996, **118**, 1931; (e) L.A. Paquette, T.M. Mitzel, M.B. Issac, C.F. Crasto and W.W. Schomer, *J. Org. Chem.*, 1997, **62**, 4293; (f) M. Carda, E. Castillo, S. Rodriguez, J. Murga and J.A. Marco, *Tetrahedron Assymetry*, 1998, **9**, 1117; (g) L.A. Paquette and P.C. Lobben, *J. Org. Chem.*, 1998, **63**, 5604.
- H. Singh, Dolly, S.S. Chimni and S. Kumar, *J. Chem. Res. (S)*, 1998, 352.
- R.J. Deshpande, *Ind. J. Chem.*, 1978, **16B**, 389.